论文部分内容阅读
作者对75例开始长程肾上腺皮质激素治疗的哮喘患者分别使用吸入Beclomethasone,倍他米松和口服强的松等治疗进行比较。其中Beclomethasone组19例,倍他米松组23例,强的松组33例。发现吸入激素和口服强的松对控制哮喘发作同样有效。每天吸入400微克药物大约和每天口服强的松7.5毫克的疗效相等。但口服强的松会抑制肾上腺对tetracosactrin的反应,而吸入皮质激素则不会。口服强的松组有全身不良反应者达30％,而吸入激素组仅5％。口咽部有念珠菌感染症状。19例(吸入激素组14例,口服强的松组5例)支气管剥落细胞检查均无异常,亦无任何真菌感染征。也没有证据说明吸入激素比口服强的松会更易诱发呼吸道感染,两种治疗方法所致的呼吸道感染发病率同样是低的。在哮喘患者的维持治疗中吸入Beclomethasone,倍他米松无胜于口服强的松。但如在正规使用激素吸入疗法期间又有哮喘发作,则必需作短程大剂量激素的全身治疗,因为在有严重气道阻塞时,吸和入激素
The authors compared 75 patients with asthma who started long-term adrenal cortical hormone therapy with inhaled Beclomethasone, betamethasone, and oral prednisone respectively. Among them, 19 were Beclomethasone group, 23 were betamethasone group and 33 were prednisone group. Inhaled hormones and oral prednisone were found to be equally effective in controlling asthma attacks. Inhalation of 400 micrograms of drug per day is approximately equal to the daily oral prednisone of 7.5 mg. However, prednisone orally suppresses the adrenal response to tetracosactrin, whereas inhaled corticosteroids do not. Oral prednisone group had 30% of systemic adverse reactions, while inhaled hormone group only 5%. Oropharyngeal symptoms of Candida infection. 19 cases (inhaled hormone group 14 cases, oral prednisone group 5 cases) bronchial exfoliated cells were normal, nor any signs of fungal infection. There is also no evidence that inhaled corticosteroids are more likely to cause respiratory infections than oral prednisone, and that the incidence of respiratory infections caused by both therapies is similarly low. Beclomethasone is inhaled during maintenance therapy in patients with asthma, and betamethasone is no better than oral prednisone. However, if there is an asthma attack during the regular use of hormone inhaled therapy, then systemic treatment of short-range, high-dose hormones is necessary because, in the presence of severe airway obstruction,